Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARP app-guided triggered acute cardiovascular risk prevention
ACTRN12625000463471Phase 2Recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of propranolol and aspirin in cardiac morbidity (2 arms), sponsored by Northern Sydney Local Health District. Primary endpoints: Change in anger and stress composite, Screening-to-randomisation rate and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
propranololaspirin
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on ACTRN12625000463471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000463471.